Literature DB >> 23450505

Melatonin modulates aromatase activity and expression in endothelial cells.

Virginia Alvarez-García1, Alicia González, Carlos Martínez-Campa, Carolina Alonso-González, Samuel Cos.   

Abstract

Melatonin is known to suppress the development of endocrine-responsive breast cancers by interacting with the estrogen signaling pathways. Paracrine interactions between malignant epithelial cells and proximal stromal cells are responsible for local estrogen biosynthesis. In human breast cancer cells and peritumoral adipose tissue, melatonin downregulates aromatase, which transforms androgens into estrogens. The presence of aromatase on endothelial cells indicates that endothelial cells may contribute to tumor growth by producing estrogens. Since human umbilical vein endothelial cells (HUVECs) express both aromatase and melatonin receptors, the aim of the present study was to evaluate the ability of melatonin to regulate the activity and expression of aromatase on endothelial cells, thus, modulating local estrogen biosynthesis. In the present study, we demonstrated that melatonin inhibits the growth of HUVECs and reduces the local biosynthesis of estrogens through the downregulation of aromatase. These results are supported by three lines of evidence. Firstly, 1 mM of melatonin counteracted the testosterone-induced cell proliferation of HUVECs, which is dependent on the local biosynthesis of estrogens from testosterone by the aromatase activity of the cells. Secondly, we found that 1 mM of melatonin reduced the aromatase activity of HUVECs. Finally, by real‑time RT-PCR, we demonstrated that melatonin significantly downregulated the expression of aromatase as well as its endothelial-specific aromatase promoter region I.7. We conclude that melatonin inhibits aromatase activity and expression in HUVECs by regulating gene expression of specific aromatase promoter regions, thereby reducing the local production of estrogens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23450505     DOI: 10.3892/or.2013.2314

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Melatonin activity and receptor expression in endometrial tissue and endometriosis.

Authors:  A A Mosher; M W Tsoulis; J Lim; C Tan; S K Agarwal; N A Leyland; W G Foster
Journal:  Hum Reprod       Date:  2019-07-08       Impact factor: 6.918

Review 2.  Circadian System and Melatonin Hormone: Risk Factors for Complications during Pregnancy.

Authors:  F J Valenzuela; J Vera; C Venegas; F Pino; C Lagunas
Journal:  Obstet Gynecol Int       Date:  2015-03-02

3.  The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Authors:  Richard E Kast; Nicolas Skuli; Samuel Cos; Georg Karpel-Massler; Yusuke Shiozawa; Ran Goshen; Marc-Eric Halatsch
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-07-11

4.  What is known about melatonin, chemotherapy and altered gene expression in breast cancer.

Authors:  Carlos Martínez-Campa; Javier Menéndez-Menéndez; Carolina Alonso-González; Alicia González; Virginia Álvarez-García; Samuel Cos
Journal:  Oncol Lett       Date:  2017-02-10       Impact factor: 2.967

Review 5.  Melatonin as a Radio-Sensitizer in Cancer.

Authors:  Carolina Alonso-González; Alicia González; Javier Menéndez-Menéndez; Carlos Martínez-Campa; Samuel Cos
Journal:  Biomedicines       Date:  2020-07-27

6.  Sleep duration and the risk of cancer: a systematic review and meta-analysis including dose-response relationship.

Authors:  Yuheng Chen; Fengwei Tan; Luopei Wei; Xin Li; Zhangyan Lyu; Xiaoshuang Feng; Yan Wen; Lanwei Guo; Jie He; Min Dai; Ni Li
Journal:  BMC Cancer       Date:  2018-11-21       Impact factor: 4.430

7.  Melatonin Modulation of Radiation and Chemotherapeutics-induced Changes on Differentiation of Breast Fibroblasts.

Authors:  Alicia González-González; Enrique García Nieto; Alicia González; Cristina Sánchez-Fernández; Carolina Alonso-González; Javier Menéndez-Menéndez; José Gómez-Arozamena; Samuel Cos; Carlos Martínez-Campa
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

8.  Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review).

Authors:  Samuel Cos; Virginia Alvarez-García; Alicia González; Carolina Alonso-González; Carlos Martínez-Campa
Journal:  Oncol Lett       Date:  2014-05-30       Impact factor: 2.967

Review 9.  A Multi-Oscillatory Circadian System Times Female Reproduction.

Authors:  Valérie Simonneaux; Thibault Bahougne
Journal:  Front Endocrinol (Lausanne)       Date:  2015-10-20       Impact factor: 5.555

Review 10.  Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers.

Authors:  Javier Menéndez-Menéndez; Carlos Martínez-Campa
Journal:  Int J Endocrinol       Date:  2018-10-02       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.